Vaccine Sales Analysis 2016-2026

Apr 06, 2016, 09:00 ET from Visiongain

LONDON, April 6, 2016 /PRNewswire/ --

Discover Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases

Vaccines - Your 2016 Guide to Developments, Opportunities and Revenues
What does the future hold for vaccine sales? Visiongain's updated report shows you forecasted sales at overall world market, submarket, product and national level to 2026.

With that study you discover vaccine trends, R&D and revenue prospects for human healthcare. That way you can benefit your research, analysis, decisions and authority. For those technologies, assess sales potentials and opportunities.

Vaccines still hold great technological, medical and commercial potential. See why and what is possible. Read on, then, to explore that industry and see a revenue prediction.

Forecasts from 2016 to 2026 and other analyses showing you vaccine market potentials
Besides revenue forecasting to 2026, our new study gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

Our report gives you 52 tables and 56 charts. Gain analysis found nowhere else. Discover what the future holds for companies and the vaccines market.

Gains through exploring the vaccines industry - ways to benefit your plans and decisions
Leaders hold the latest knowledge - research and analysis. So explore, in our report, the development, production and sales of vaccines. There, from 2016, you see where needs and money exist for those preventative medicines. Discover what is possible.

Our study's purpose is to help you avoid struggles to gain business data on vaccines. See how our predictions and discussions could benefit your reputation for commercial insight.

Discover, then, how you and your organisation can gain. The following sections show how our new investigation benefits your plans, decisions and presentations.

Revenues for the world vaccines market and submarkets - what is possible?
What is that industry's potential? What are the secrets of its progress? Discover in our report

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

overall world revenue forecasting to 2026. Also find individual predictions for four world level submarkets:
• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.

How will sales rise? And which product classes can generate most revenue? In our work you assess prospects for commercial expansion. You see which vaccine types hold greatest potential for sales growth and high revenues.

Benefit your knowledge and authority. You also discover sales potentials of vaccines by brand.

Forecasts and discussions for leading marketed products
How will leading brands perform from 2016 at world level? Our work shows you 10 individual revenue forecasts to 2026 for leading vaccines:
• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad/M-M-R- II/Varivax.

You also see revenue predictions to 2026 for these products:
• Infanrix/Pediarix
• Zostavax
• RotaTeq
• GSK hepatitis franchise
• Menactra.

Avoid falling behind in information to help you stay competitive. Instead our work lets you assess potentials, seeing activities, results and outlooks. You discover what is happening, exploring trends, competition and sales prospects.

Our study also divides its overall world vaccines forecast into geographical regions.

Healthcare in national markets - what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare from 2016 will increase vaccination. With our investigation you hear about the best revenue prospects for those medicines, assessing national prospects.

Our analysis shows you individual revenue forecasts to 2026 for 11 national markets:
United States (US)
Japan
Germany, France, United Kingdom, Italy and Spain (EU5 countries)
Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and future sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Future vaccines - assess emerging technologies, exploring research and development
Our study also shows you the most promising vaccines in development. There explore product candidates in these six classes:
• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.

R&D for vaccines holds great potential to benefit companies, healthcare providers and patients. See what technological, clinical and commercial opportunities exist, helping you stay ahead.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers and sellers of vaccines
Assess forces affecting that industry and market from 2016, including these issues:
• Importance of vaccine production to the pharmaceutical industry
• Immunisation needs and progress in developed and developing countries
• Rising vaccination needs in emerging countries and under-developed regions, including fighting influenza pandemics and the Zika virus
• Developments for combating HIV, cancer, addictions and other emerging uses
• Delivery systems and other innovations improving vaccines' performance.

With our survey you explore political, economic, social and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market, seeing what the future holds.

Leading vaccine producers and that industry's overall 2020 market value
What happens next? Our report predicts the overall world market for vaccines will reach $49.8bn worldwide in 2020, with strong revenue expansion from 2016 to 2026.

See how high its revenues can go. Discover in our work what is possible for vaccine production and sales, and see which companies hold greatest potential.

In particular our work assesses these organisations:
• GlaxoSmithKline
• Merck & Co.
• Sanofi
• Pfizer
• Johnson & Johnson
• AstraZeneca.

From 2016 to 2026 vaccines will benefit patients, payers and companies, rising in prominence. Our analysis predicts advances there. Stay ahead by getting that study.

Ways Vaccine Sales 2016-2026 benefits your work - gain data you find nowhere else
In particular, our new investigation gives you these analyses to help your research, plans, decisions and proposals:
• Revenues to 2026 for vaccines at world level and for 4 main submarkets - assess prospects for investments, marketing and sales
• Predictions for 10 products to 2026 - discover revenue potentials of leading vaccines, seeing how they can compete and succeed
• Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors and rising companies - explore products, R&D and outlooks for success.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

With our study, by visiongain's UK-based analysts, you avoid missing out on data to help you stay ahead. See what the future holds for vaccine developers, producers and sellers.

Trying our new report now lets you discover vaccine trends, opportunities and forecasts
Our investigation is for everyone analysing preventive medicines and related biotechnology. There you discover data and forecasts for human vaccines. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1608/Vaccine-Sales-Analysis-2016-2026

Companies and Other Organisations Mentioned in the Report
Aduro Biotech
Advisory Committee for Immunization Practices (ACIP)
Aspen
Astellas
Asterias Biotherapeutics
AstraZeneca
Bavarian Nordic
Baxter
Bayer
Bharat Biotech
Bill & Melinda Gates Foundation
Binnopharm
BiondVax
BravoBio
Brazilian Universal Health Service
Butantan Institute
Cancer Research UK
Center for Biologics Evaluation and Research (CBER)
Centers for Disease Control and Protection (CDC)
China National Biotec Group
China's National Regulatory Authority (CNRA)
Chinese Food and Drug Administration (CFDA)
Crucell
Developing Countries Vaccine Manufacturers Network (DCVMN)
Dubai Investments PJSC
Eli Lilly
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Fresenius
GlaxoSmithKline (GSK)
Global Alliance for Vaccines and Immunization (GAVI)
Globalpharma
Health Service Bureau
Henogen
HIV Vaccines Trial Network
Immatics
Indian Department of Biotech
InnoPharma
Inovio Pharmaceuticals
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
International Medica Foundation
InterveXion Therapeutics
Inviragen
Johnson & Johnson
Krka
LigoCyte Pharmaceuticals
Lupin Pharmaceutical
MedImmune
Merck & Co.
Ministry of Health, Labour and Welfare
NewLink Genetics
Novartis
Okairos
Pan American Health Alliance (PAHO)
Pfizer
Profectus BioSciences
Regulus Therapeutics
Roche
Rosteh
Sanofi Pasteur
Servizio Sanitario Nazionale (SSN)
Shanghai BravoBio
Shionogi
Sistema Único de Saúde (SUS)
Takeda
Themis Bioscience
UK National Health Service (NHS)
Unicef
US Department of Health and Human Services (HHS)
US National Cancer Institute
World Health Organization (WHO)
Zymeworks

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


SOURCE Visiongain